Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction Still Lacks Many Study Results, JAMA Finds; Do Transparency Efforts Need A Boost?

Executive Summary

Industry data transparency initiatives are well-established now, but JAMA study suggests holes in efforts to publicly release clinical trial results.

Related Content

US FDA Threatens Fines For Noncompliance
Boost For Transparency As EU Court Backs EMA's Approach To Disclosing Clinical Data
Clinical Study Disclosures Will Make Drug Reviews More Efficient – Gottlieb
Clinical Trial Challenges: FDA Wants More Prospective Studies, Validated Biomarkers
Clinical Data Disclosure Embraced By Pharma; Now It Needs Partners
Clinical Data Disclosure: PhRMA Principles Rely On Review Boards To Screen Research Proposals





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts